Related Experiment Video
Updated: Jul 3, 2026
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Mortality related to neoadjuvant therapy and surgery for stage III non-small-cell lung cancer
Gerald H Clamon1, Kalpaj R Parekh
1Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA. gerald-clamon@uiowa.edu
Background:
Neoadjuvant chemotherapy alone or with concurrent radiation is often used for stage IIIA non-small-cell lung cancer but is often tried in patients with stage IIIB and at times in patients with stage I or II disease. Newer neoadjuvant regimens would need to be compared with currently used programs to see if they increased toxicity. For such a comparison, a baseline estimate is needed of the mortality of currently used regimens.
Patients And Methods:
In this review, we searched PubMed and associated references, and data on mortality were identified in 34 publications.
Results:
The mortality of neoadjuvant chemotherapy or chemotherapy plus radiation has been estimated in 2015 patients was 0.7%, and the postsurgical mortality in 2195 patients was 4.3%.
Conclusion:
These estimates might provide a benchmark for comparison for innovative trials.
